Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial

ABSTRACT Background Lung cancer is a leading cause of cancer‐related deaths. Perioperative therapies, including neoadjuvant chemo‐immunotherapy, have improved outcomes, but combining them with antiangiogenic drugs may offer further benefits. This study evaluated the 3‐year efficacy and safety of neo...

Full description

Bibliographic Details

Published in:	Thoracic Cancer
Main Authors:	Zhiyuan Gao, Yajie Mao, Yichen Sun, Liping Tong, Honggang Liu, Tianhu Wang, Changjian Shao, Hongtao Duan, Xiaolong Yan
Format:	Article
Language:	English
Published:	Wiley 2025-08-01
Subjects:	antiangiogensis follow‐up neoadjuvant NSCLC TD‐NeoFOUR
Online Access:	https://doi.org/10.1111/1759-7714.70149